Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.20
$0.31
$0.12
▼
$1.05
N/AN/A4,526 shsN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
$0.01
$0.01
▼
$0.23
N/AN/A49,664 shs200 shs
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.21
+40.8%
$0.29
$0.05
▼
$0.98
N/AN/A4,682 shs605 shs
NKGNW
NKGen Biotech
$0.00
$0.00
$0.00
▼
$0.11
N/AN/A211,125 shsN/A
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%+42.86%-55.52%-8.05%-77.53%
Apollomics, Inc. stock logo
APLMW
Apollomics
+2.94%+2.94%+3.96%-34.78%-37.13%
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00%+28.48%+39.47%+76.67%-37.65%
NKGNW
NKGen Biotech
0.00%0.00%0.00%-33.33%-83.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.20
$0.31
$0.12
▼
$1.05
N/AN/A4,526 shsN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
$0.01
$0.01
▼
$0.23
N/AN/A49,664 shs200 shs
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.21
+40.8%
$0.29
$0.05
▼
$0.98
N/AN/A4,682 shs605 shs
NKGNW
NKGen Biotech
$0.00
$0.00
$0.00
▼
$0.11
N/AN/A211,125 shsN/A
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%+42.86%-55.52%-8.05%-77.53%
Apollomics, Inc. stock logo
APLMW
Apollomics
+2.94%+2.94%+3.96%-34.78%-37.13%
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00%+28.48%+39.47%+76.67%-37.65%
NKGNW
NKGen Biotech
0.00%0.00%0.00%-33.33%-83.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00
N/AN/AN/A
NKGNW
NKGen Biotech
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$489.61MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$5.47MN/AN/AN/AN/AN/A
NKGNW
NKGen Biotech
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/AN/AN/AN/A11/18/2026 (Estimated)
NKGNW
NKGen Biotech
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/A
NKGNW
NKGen Biotech
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
NKGNW
NKGen Biotech
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
NKGNW
NKGen Biotech
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
1,460N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
15N/AN/ANot Optionable
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
57N/AN/ANot Optionable
NKGNW
NKGen Biotech
63N/AN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.20 0.00 (0.00%)
As of 11/16/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.01 0.00 (0.00%)
As of 11/16/2026 01:57 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

bioAffinity Technologies stock logo

bioAffinity Technologies NASDAQ:BIAFW

$0.21 +0.06 (+40.77%)
Closing price 11/16/2026 03:59 AM Eastern
Extended Trading
$0.21 0.00 (0.00%)
As of 11/16/2026 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

NKGen Biotech NASDAQ:NKGNW

$0.0002 0.00 (0.00%)
As of 11/6/2026

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.